Background: Globally, mild asthma accounts for 50- 75% of all asthma patients1 and around half of mild asthmatics are uncontrolled.2 Characteristics of mild asthma patients are not fully elucidated, especially in the Korean population. Methods: SYGMA 1 & 2 (NCT02149199; NCT02224157) were randomized, double-blind, placebo-controlled, multinational trials designed to evaluate the efficacy and safety of as-needed budesonide/formoterol as anti-inflammatory reliever in mild asthma patients.3,4 This subgroup analysis evaluated baseline characteristics of Korean patients with mild asthma from the SYGMA 1 & 2 studies. Results: In total 160 and 133 Korean patients were enrolled to SYGMA 1 & 2, respectively. In Korean patients, median time since asthma diagnosis was 6.0 years for SYGMA 1 and 4.6 years for SYGMA 2. At study entry, 79.2% of SYGMA 1 population and 90.2% of SYGMA 2 population were controlled on ICS or LTRA; the remainder were uncontrolled on short-acting bronchodilators alone. Mean pre-bronchodilator FEV1 was 89.9% for SYGMA 1 and 90.4% for SYGMA 2. Mean bronchodilator reversibility was 8.35% for SYGMA 1 and 8.69% for SYGMA 2. Some 19.5% of patients from SYGMA 1 and 20.3% of patients from SYGMA 2 experienced one or more severe exacerbation in the prior year; similar to the overall study population. (Table 1) Conclusions: Compared to overall study results, Korean mild asthma patients showed better lung function and a lower proportion of enrolled patients were previously uncontrolled on short-acting bronchodilators. But, history of severe exacerbation was similar to the overall study populations. Further evidence would be helpful to understand clinical features of mild asthma patients in Korea. 2. Olaguibel et al. Respir Res. 2012,13:50. 3. O’Byrne et al. N Engl J Med. 2018;378:1865-76. 4. Bateman et al. N Engl J Med. 2018;378:1877-87.